Detalhe da pesquisa
1.
Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.
Am J Hematol;
99(3): 380-386, 2024 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38258329
2.
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia.
Hematol Oncol;
41(4): 743-752, 2023 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37086447
3.
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Blood;
135(24): 2137-2145, 2020 06 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32219442
4.
A prospective study of the use of central venous catheters in patients newly diagnosed with acute myeloid leukemia treated with induction chemotherapy.
Support Care Cancer;
30(2): 1673-1679, 2022 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34562168
5.
Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
Future Oncol;
17(35): 4959-4969, 2021 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34783255
6.
Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy.
Blood;
140(25): 2754-2756, 2022 12 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36112968
7.
Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.
Cytotherapy;
19(10): 1225-1232, 2017 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28864289
8.
Outcomes of patients diagnosed with acute myeloid leukemia after solid organ transplantation.
Clin Transplant;
31(9)2017 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28710776
9.
Outcome of acute myeloid leukemia patients with pulmonary nodules of uncertain etiology receiving allogeneic hematopoietic progenitor cell transplant.
Eur J Haematol;
96(1): 55-9, 2016 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25784319
10.
Peri-transplant clostridium difficile infections in patients undergoing allogeneic hematopoietic progenitor cell transplant.
Am J Hematol;
91(3): 291-4, 2016 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26661725
11.
Hypomethylating Agents for Relapse after Allogeneic Hematopoietic Cell Transplantation in Myeloid Malignancies: A Case Series and Review of the Literature.
Acta Haematol;
135(4): 232-7, 2016.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27007668
12.
Leukapheresis in patients newly diagnosed with acute myeloid leukemia.
Transfus Apher Sci;
55(2): 216-220, 2016 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27470709
13.
Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy.
Am J Hematol;
90(8): 715-8, 2015 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26010177
14.
Patient and family caregiver dyadic adherence to the allogeneic hematopoietic cell transplantation medical regimen.
Psychooncology;
27(1): 354-358, 2018 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28181721
15.
Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences.
Target Oncol;
18(5): 727-734, 2023 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37728835
16.
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.
Blood Adv;
7(22): 7141-7150, 2023 11 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37722354
17.
Rates and Predictors of Nonadherence to the Post-Allogeneic Hematopoietic Cell Transplantation Medical Regimen in Patients and Caregivers.
Transplant Cell Ther;
28(3): 165.e1-165.e9, 2022 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34875403
18.
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting.
J Hematol Oncol;
14(1): 66, 2021 04 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33879198
19.
Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission.
Oncol Res;
28(7): 811-814, 2021 Sep 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32753091
20.
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).
Blood Cancer J;
11(10): 163, 2021 10 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34599139